Abstract
Background:
After cardiac surgery, central venous oxygen saturation (ScvO2) and serum lactate concentration are often used to guide resuscitation; however, neither are completely reliable indicators of global tissue hypoxia. This observational study aimed to establish whether the ratio between the veno-arterial carbon dioxide and the arterial-venous oxygen differences (P(v−a)CO2/C(a−v)O2) could predict whether patients would respond to resuscitation by increasing oxygen delivery (DO2).
Methods:
We selected 72 patients from a cohort of 290 who had undergone cardiac surgery in our institution between January 2012 and August 2014. The selected patients were managed postoperatively on the Intensive Care Unit, had a normal ScvO2, elevated serum lactate concentration, and responded to resuscitation by increasing DO2 by >10%. As a consequence, 48 patients responded with an increase in oxygen consumption (VO2) while VO2 was static or fell in 24.
Results:
At baseline and before resuscitative intervention in postoperative cardiac surgery patients, a P(v−a)CO2/C(a−v)O2 ratio ≥1.6 mmHg/ml predicted a positive VO2 response to an increase in DO2 of >10% with a sensitivity of 68.8% and a specificity of 87.5%.
Conclusions:
P(v−a)CO2/C(a−v)O2 ratio appears to be a reliable marker of global anaerobic metabolism and predicts response to DO2 challenge. Thus, patients likely to benefit from resuscitation can be identified promptly, the P(v−a)CO2/C(a−v)O2 ratio may, therefore, be a useful resuscitation target.
Keywords: Cardiac Surgical Procedures, Lactic Acid, Physiologic Monitoring, Resuscitation
INTRODUCTION
Hyperlactatemia is common after cardiac surgery. Impaired tissue oxygenation leads to increased anaerobic metabolism and production of pyruvate, which is subsequently converted to lactate. Numerous studies have established the use of serum lactate concentration as a marker of global tissue hypoxia in circulatory shock, but after cardiac surgery hyperlactatemia may occur as a result of other mechanisms, such as the stress response to surgery and the use of β-adrenergic,[1,2] and other diseases also have reported, such as sepsis.[3,4] Therefore, after cardiac surgery, hyperlactatemia may not be a reliable means of judging the adequacy of tissue oxygenation.
A normal central venous oxygen saturation (ScvO2) generally indicates that oxygen delivery (DO2) is sufficient to meet oxygen consumption (VO2), and further increasing DO2 is not necessary. A persistently normal ScvO2 and decreasing serum lactate concentration normally reflects a resolving oxygen deficit, and that any oxygen debt is being repaid. Nevertheless, ScvO2 may not reflect tissue hypoxia when VO2 is impaired by mitochondrial dysfunction or cytopathic hypoxia,[5] or when microcirculatory failure results in shunting of blood away from metabolically active but hypoxic tissues.[6] Therefore, neither ScvO2 nor serum lactate concentration can be completely relied upon to detect clinically important anaerobic metabolism. It may not be clear how to manage cardiac surgical patients with a normal ScvO2 and hyperlactatemia, and the inappropriate use of excessive volume expansion or positive inotropic agents carries substantial risks.
It is important, therefore, to find reliable indices to predict when an increase in DO2 will reduce the oxygen debt, reflected by an increase in VO2. A recent study showed that the ratio between veno-arterial carbon dioxide difference and arterial-venous oxygen difference (P(v−a)CO2/C(a−v)O2) is a hallmark of oxygen deficit caused by acute circulatory failure.[7]
As oxygen supply dependency, reflected by derangements in the relationship between VO2 and DO2, is a hallmark of acute circulatory failure.[8] We hypothesized that P(v−a) CO2/C(a−v)O2 can be used as an index of global tissue hypoxia in cardiac surgery patients. We undertook serial measurements of VO2 because DO2 changed after cardiac surgery to illuminate the relationship between the two parameters.
METHODS
We prospectively collected the data of a cohort of consecutive adults who underwent cardiac surgery between January 2012 and August 2014 at the Peking Union Medical College Hospital (PUMCH), and were admitted to the 15-bed general Intensive Care Unit (ICU) for postoperative care. The Institutional Research and Ethics Committee of the PUMCH approved this study for human subjects. Because the laboratory tests undertaken and the data collected were part of routine clinical practice, the study was observational and thus informed consent was not required.
Patients
We collected data from patients with hyperlactatemia and normal ScvO2, and in whom changes in therapy during the first 6 h of postoperative care resulted in changes in DO2. During the study period, 290 patients after cardiac surgery were admitted to the ICU and received pulse contour continuous cardiac output (PiCCO) monitoring (PiCCO; Pulsion Medical Systems, Munich, Germany). Indications for PiCCO catheterization were: Left ventricular ejection fraction <45%; history of myocardial infarction; resection of a ventricular aneurysm; repeat coronary artery bypass grafting; left main or complex coronary artery disease; replacement of two valves; and hemodynamic instability. Two hundred and twenty-one were found to have hyperlactatemia and normal ScvO2. Inclusion criteria were: A serum lactate concentration >2 mmol/L; ScvO2 >60.8% on admission to the ICU (considered the normal ScvO2 for cardiac surgical patients);[9] and resuscitation that resulted in changes in DO2 of >10%.[8]
The interventions made to improve the DO2 were chosen at the discretion and clinical judgment of the attending physicians. Of the 221 patients, interventions were made to improve DO2 in 123; the remaining 98 were managed supportively and observed for improvement in serum lactate concentration. Of those patients in whom an intervention was made, an improvement of DO2 ≥10% was only seen in 72 (58.5%). A patient flow chart is shown in Figure 1.
Figure 1.

Study flow chart. PiCCO: Pulse contour continuous cardiac output; ScvO2: Central venous oxygen saturation; DO2: Oxygen delivery.
Measurements
Arterial pressure and heart rate were monitored continuously using a femoral artery catheter and the PiCCO plus device (Pulsion Medical Systems, Munich, Germany). Clinical strategies to improve DO2 included intravenous fluid challenges and the use of positive inotropic agents. If the stroke volume variation (SVV) (measured in patients in sinus rhythm who were mechanically ventilated and fully adapted to the ventilator settings) exceeded 13%, a fluid challenge was given until the SVV fell below 13%. Thereafter, if the cardiac index (CI) was <2.5 L·min−1·m−2, dobutamine, milrinone or epinephrine was administered as an intravenous infusion to achieve a CI >2.5 L·min−1·m−2. The doses of inotropes were moderated in the presence of cardiac arrhythmia. If there was severe hypotension (systolic blood pressure ≤60 mmHg), norepinephrine was administered as an intravenous infusion, but the dose titrated so that the systemic vascular resistance index (SVRI) did not exceed 2500 dyn·s-1·cm-5·m-2. After each intervention, CI, stroke volume index, global end-diastolic volume index (GEDVI), and SVRI were measured using a transpulmonary thermodilution technique with the mean cardiac output (CO) of three measurements within 10% of each other used to calculate each variable. All measurements were undertaken in a stable environment in the absence of any other intervention likely to alter oxygen demand or delivery, such as changes in sedation, physiotherapy, and tracheobronchial toilet. Arterial and central venous blood samples were taken for measurement of acid-base status (Abl 3 Automated Blood Gas Analyzer, Radiometer, Copenhagen, Denmark), hemoglobin (Hb) concentration, and oxygen saturation (Hemoximeter, OSM 3, Radiometer, Copenhagen, Denmark). Arterial lactate concentrations were determined enzymatically (Hitachi Analyzer, Tokyo, Japan). The normal blood lactate value for our laboratory was <2.0 mmol/L. Oxygen-derived variables were calculated using standard formulae. Veno-arterial carbon dioxide difference (P(v−a)CO2) and the ratio of P(v−a)CO2/C(a−v)O2 were calculated using the following formulae:
P(v−a)CO2 = PvCO2 − PaCO2.
Ratio = P(v−a)CO2/(CaO2 −CvO2).
The anion gap (AG) was calculated as follows:
AG = ([Na+] + [K+]) − ([Cl−] + [HCO3−]) and corrected for the effect of abnormal albumin concentration thus: Corrected anion gap (AGcorrected) (mmol/L) = AG + 0.25× (normal albumin − observed albumin) (g/L).[10]
Finally, we divided patients who responded to interventions to improve DO2 into two groups on the basis of the resultant change in VO2: In the first group, an improvement in VO2 was observed (∆VO2 >0%, the “VO2 increase group”); in the second VO2 remained unchanged or declined (∆VO2 ≤0% the “VO2 no-increase group”).
Statistical analysis
A descriptive analysis was undertaken. All normally distributed data were expressed as the mean ± standard deviation (SD) unless otherwise specified. Differences between baseline variables and those recorded after intervention in the two groups were tested for statistical significance using the independent-samples t-test for continuous data and the Chi-square test for categorical variables. All comparisons were two-tailed, and P < 0.05 was required to exclude the null hypothesis. We also constructed receiver operator characteristic (ROC) curves to test the ability of the P(v−a)CO2/C(a−v)O2 ratio at baseline to predict an increase in VO2 in patients in whom DO2 responded to intervention. The areas under the ROC curves (AUCs) are expressed as mean (95% confidence interval [CI]) and were compared using the Hanley–McNeil test. All statistical analyses were undertaken using the SPSS software package (version 13.0, SPSS, Chicago, IL, USA).
RESULTS
Seventy-two patients admitted the ICU after cardiac surgery fulfilled the inclusion criteria [Figure 1]. On admission, their mean baseline ScvO2 was 75.3% ± 6.9% and serum lactate concentration 5.6 ± 3.1 mml/L; their demographic and physiological data and outcomes are shown in Table 1.
Table 1.
Characteristics of patients after cardiac surgery
| Characteristics | Values |
|---|---|
| Age (mean ± SD), years | 54 ± 19 |
| Sex (male/female), n | 42/30 |
| Body mass index (mean ± SD), kg/m2 | 23.5 ± 3.0 |
| APACHE II score (mean ± SD) | 19.6 ± 8.6 |
| Type of surgery, n | |
| Coronary artery bypass graft | 27 |
| Valve replacement | 33 |
| Aortic | 18 |
| Mitral | 12 |
| Aortic + mitral | 3 |
| Pulmonary endarterectomy | 4 |
| Resection of cardiac tumor | 6 |
| Fontan procedure | 2 |
| Preoperative ejection fraction, % | 58.3 ± 14.9 |
| Preoperative creatinine, μmol/L | 59.5 (53.5-98.8) |
| History, n (%) | |
| Previous myocardial infarction | 18 (25) |
| Hypertension | 33 (45.8) |
| Diabetes | 30 (41.7) |
| Cerebrovascular disease | 15 (20.8) |
| Peripheral vascular disease | 3 (4.2) |
| Emergency surgery, n (%) | 48 (66.7) |
| Preoperative cardiac shock, n (%) | 3 (4.2) |
| Use of IABP preoperatively, n (%) | 3 (4.2) |
| Use of IABP surgery, n (%) | 15 (20.8) |
| Use of IABP after surgery, n (%) | 9 (12.5) |
| Patients receiving vasopressor | |
| Norepinephrine, n (%) | 57 (79.2) |
| Norepinephrine dose (mean ± SD), μg∙kg−1∙min−1 | 0.39 ± 0.40 |
| Patients receiving inotropic agent | |
| Dobutamine, n (%) | 9 (12.5) |
| Dobutamine dose (mean ± SD), μg∙kg−1∙min−1 | 2.99 ± 2.56 |
| Epinephrine, n (%) | 54 (75) |
| Epinephrine dose (mean ± SD), μg∙kg−1∙min−1 | 0.24 ± 0.53 |
| Milrinone, n (%) | 36 (50) |
| Milrinone dose (mean ± SD), μg∙kg−1∙min−1 | 0.37 ± 0.20 |
| DO2 (mean ± SD), ml∙min−1∙m−2 | 438.2 ± 138.6 |
| VO2 (mean ± SD), ml∙min−1∙m−2 | 102.5 ± 35.4 |
| ERO2, % | 24.6 ± 9.4 |
| ScvO2, % | 75.3 ± 6.9 |
| Lactate (mean ± SD), mmol/L | 5.6 ± 3.1 |
| P(v−a)CO2 (mean ± SD), mmHg | 5.8 ± 2.5 |
| P(v−a)CO2/C(a−v)O2 ratio (mean ± SD), mmHg/ml | 1.9 ± 1.1 |
| AGcorrected (mean ± SD), mmol/L | 18.8 ± 4.5 |
| Length ICU stay, days | 8.9 ± 5.7 |
| Length hospital stay, days | 42.8 ± 20.9 |
| Mortality at day 28, % | 16.7 |
APACHE II: Acute physiological and chronic health evaluation II score; IABP: Intra-aortic balloon pump; DO2: Oxygen delivery; VO2: Oxygen consumption; ERO2: Oxygen extraction ratio; ScvO2: Central venous oxygen saturation; AGcorrected: Corrected anion gap; P(v-a)CO2: Veno-arterial carbon dioxide difference; C(a-v)O2: Arterial-venous oxygen difference; ICU: Intensive Care Unit; SD: Standard deviation.
Clinical management
Improvements in DO2 were achieved using one or more of the following strategies: Intravenous fluid challenge (n = 58); dobutamine (n = 9), milrinone (n = 36) or epinephrine (n = 58) infusion; blood transfusion (n = 9); or an increase the positive end-expiratory pressure (n = 2). Data from the 72 patients demonstrated that changes in VO2 (101 ± 35 vs. 126 ± 47 ml·min−1·m−2; P = 0.003) paralleled changes in DO2 (438 ± 139 vs. 531 ± 159 ml·min−1·m−2; P < 0.001). Of the patients in whom DO2 improved by >10%, VO2 improved in 48 patients (∆VO2 >0%), but not in 24 (∆VO2 ≤0%).
Differences between the oxygen consumption (VO2) increase and VO2 no-increase groups
There were no significant differences between the groups in terms of baseline patient characteristics, such as acute physiology and chronic health evaluation II scores, preoperative ejection fraction, and New York Heart Association functional heart failure class. There were also no differences in terms of surgery characteristics, such as cardiopulmonary bypass (CPB) time and aortic cross-clamping time. There were also no significant physiological differences between the groups, such as the lowest mean arterial pressure during CPB, the highest serum lactate concentration, the lowest base excess, the lowest serum bicarbonate concentration or the volume of blood transfused. Finally, there were no significant differences in the need for postoperative vasopressor and inotropic agents [Table 2].
Table 2.
Physiological and surgical characteristics of the VO2 increase and VO2 no-increase groups
| Characteristics | VO2 increase group (n = 48) | VO2 no-increase group (n = 24) | P |
|---|---|---|---|
| APACHE II scores on admission to ICU (mean ± SD) | 18.6 ± 8.5 | 21.4 ± 8.8 | 0.460 |
| Preoperative left ventricular ejection fraction, % | 57.5 ± 16.4 | 60.1 ± 12.1 | 0.706 |
| Preoperative NYHA heart failure class, n | |||
| I | 0 | 3 | 0.502 |
| II | 15 | 6 | |
| III | 24 | 9 | |
| IV | 9 | 6 | |
| The percentage of accepted CPB | 100 | 100 | |
| CPB time, min | 114.4 ± 47.6 | 116.4 ± 32.9 | 0.916 |
| Aortic cross-clamp time, min | 72.8 ± 34.2 | 79.5 ± 27.8 | 0.634 |
| Lowest MAP during CPB, mmHg | 60.6 ± 12.1 | 60.5 ± 8.2 | 0.979 |
| Blood transfusion during surgery (median [IQR]), units | 4 [0−4] | 4 [2.25−5.50] | 0.312 |
| Lowest lactate during CPB (mean ± SD), mmol/L | 5.3 ± 3.4 | 4.9 ± 2.1 | 0.785 |
| Lowest base excess during CPB (mean ± SD), mmol/L | −4.4 ± 3.0 | −4.3 ± 2.2 | 0.927 |
| Lowest bicarbonate during CPB (mean ± SD), mmol/L | 21.3 ± 1.9 | 22.0 ± 1.6 | 0.4 |
| Postoperative ejection fraction at 2 weeks, % | 57.7 ± 14.7 | 61.6 ± 13.1 | 0.567 |
| Number of patients receiving a vasopressor | |||
| Norepinephrine, n (%) | 39 (81.2) | 18 (75.0) | 0.722 |
| Norepinephrine dose (mean ± SD), μg∙kg−1∙min−1 | 0.39 ± 0.43 | 0.37 ± 0.37 | 0.907 |
| Number of patients receiving an inotropic agent | |||
| Dobutamine, n (%) | 9 (18.8) | 0 (0) | 0.190 |
| Dobutamine dose (mean ± SD), μg∙kg−1∙min−1 | 2.99 ± 2.56 | ||
| Epinephrine, n (%) | 33 (68.8) | 21 (87.5) | 0.317 |
| Epinephrine dose (mean ± SD), μg∙kg−1∙min−1 | 0.11 ± 0.09 | 0.44 ± 0.84 | 0.207 |
| Milrinone, n (%) | 21 (43.8) | 15 (62.5) | 0.386 |
| Milrinone dose (mean ± SD), μg∙kg−1∙min−1 | 0.40 ± 0.23 | 0.32 ± 0.16 | 0.524 |
| Lactate clearance, % | 10.2 ± 31.5 | 8.6 ± 18.2 | 0.897 |
| Length of ICU stay, days | 9.8 ± 6.3 | 7.0 ± 3.8 | 0.263 |
| Length of hospital stay, days | 42.8 ± 21.2 | 42.8 ± 21.8 | 0.995 |
| Mortality at day 28, % | 12.5 | 25.0 | 0.439 |
APACHE II: Acute physiological and chronic health evaluation II score; NYHA: New York Heart Association; CPB: Cardiopulmonary bypass; MAP: Mean arterial pressure; IQR: Interquartile range; ICU: Intensive Care Unit; SD: Standard deviation; VO2: Oxygen consumption.
At baseline, there were significant differences in P(v−a)CO2/C(a−v)O2 ratio and VO2 between the groups (2.2 ± 1.2 vs. 1.2 ± 0.4 mmHg/ml, P = 0.030 and 88.6 ± 28.5 vs. 130.3 ± 32.4 ml·min−1·m−2, P = 0.004, respectively); however, there were no significant differences in hemodynamic (such as central venous pressure [CVP], CI, GEDVI, SVRI and extravascular lung water index), global metabolic (such as DO2 and oxygen extraction ratio [ERO2]) or tissue perfusion parameters [such as ScvO2, P(v−a)CO2, serum lactate and AGcorrected; Table 3]. After intervention, there was a significant difference in ScvO2 between the groups (73.5% ± 6.4% vs. 79.2% ± 5.7%, P = 0.043), but not in any of the other hemodynamic, global metabolic or tissue perfusion variables [Table 3].
Table 3.
Hemodynamic and metabolic variables of the VO2 increase and VO2 no-increase groups
| Variables | VO2 increase group (n = 48) | VO2 no-increase group (n = 24) | ||
|---|---|---|---|---|
| Baseline | After intervention | Baseline | After intervention | |
| CVP (mean ± SD), mmHg | 9.5 ± 3.3‡ | 12.1 ± 3.5 | 9.3 ± 2.0§ | 11.4 ± 3.7 |
| GEDVI (mean ± SD), ml/m2 | 664.1 ± 190.9 | 686.5 ± 167.0 | 672.5 ± 329.4 | 722.3 ± 333.7 |
| CI (mean ± SD), L∙min−1∙m−2 | 3.0 ± 0.8‡ | 3.7 ± 1.0 | 3.2 ± 0.7§ | 3.9 ± 0.6 |
| SVRI (mean ± SD), dyn∙s-1∙cm-5∙m-2 | 2106.7 ± 954.1‡ | 1565.9 ± 572.3 | 2106.0 ± 711.2 | 1648.9 ± 594.0 |
| EVLWI (mean ± SD), ml/kg | 7.7 ± 2.5 | 7.3 ± 2.4 | 9.1 ± 5.5 | 10.1 ± 6.1 |
| DO2 (mean ± SD), ml∙min−1∙m−2 | 408.5 ± 124.9‡ | 499.4 ± 151.9 | 497.8 ± 154.4§ | 594.9 ± 162.4 |
| VO2 (mean ± SD), ml∙min−1∙m−2 | 88.6 ± 28.5*‡ | 129.3 ± 51.9 | 130.3 ± 32.4 | 118.4 ± 37.9 |
| ERO2, % | 22.7 ± 7.7‡ | 26.0 ± 7.2 | 28.3 ± 11.7 | 20.2 ± 5.3 |
| ScvO2, % | 76.3 ± 6.7 | 73.5 ± 6.4† | 73.4 ± 7.4§ | 79.2 ± 5.7 |
| Lactate (mean ± SD), mmol/L | 5.4 ± 3.1 | 4.9 ± 3.5 | 5.9 ± 3.3 | 5.5 ± 3.1 |
| P(v-a)CO2 (mean ± SD), mmHg | 6.2 ± 2.5 | 4.3 ± 2.9 | 4.9 ± 2.2 | 3.2 ± 2.6 |
| P(v-a)CO2/C(a-v)O2 ratio (mean ± SD), mmHg/ml | 2.2 ± 1.2*‡ | 1.2 ± 0.8 | 1.2 ± 0.4 | 1.1 ± 0.8 |
| AGcorrected (mean ± SD), mmol/L | 18.1 ± 5.1 | 18.2 ± 4.9 | 20.2 ± 3.0 | 19.0 ± 4.6 |
*P < 0.05 for the VO2 increase group versus the VO2 no-increase group at baseline; †P < 0.05 for VO2 increase group versus VO2 no-increase group after intervention; ‡P < 0.05 for the difference between baseline and intervention in the VO2 increase group; §P < 0.05 for the difference between baseline and intervention in the VO2 no-increase group. CVP: Central venous pressure; GEDVI: Global end diastolic volume index; CI: Cardiac index; SVRI: Systemic vascular resistance index; EVLWI: Extravascular lung water index; DO2: Oxygen delivery; VO2: Oxygen consumption; ERO2: Oxygen extraction ratio; ScvO2: Central venous oxygen saturation; P(v−a)CO2: Veno-arterial carbon dioxide difference; AGcorrected: Corrected anion gap; SD: Standard deviation; C(a-v)O2: Arterial-venous oxygen difference.
In the VO2 increase group, DO2 increased by 23% ± 13% (P < 0.001) and VO2 by 46% ± 38% (P < 0.001). The intervention to increase DO2 by >10% significantly altered CVP (9.5 ± 3.3 vs. 12.1 ± 3.5 mmHg, P < 0.001), CI (3.0 ± 0.8 vs. 3.7 ± 1.0 L·min−1·m−2, P < 0.001), SVRI (2106.7 ± 954.1 vs. 1565.9 ± 572.3 dyn·s-1·cm-5·m-2, P = 0.002), ERO2 (22.7% ± 7.7% vs. 26.0% ± 7.2%, P = 0.047) and P(v−a)CO2/C(a−v)O2 ratio [2.2 ± 1.2 vs. 1.2 ± 0.8 mmHg/ml, P = 0.013; Table 3]. In the VO2 no-increase group, even though DO2 increased by 21% ± 11% (497.8 ± 154.4 vs. 594.9 ± 162.4 ml·min−1·m−2, P < 0.001), VO2 fell by 7% ± 10% (130.3 ± 32.4 vs. 118.4 ± 37.9 ml·min−1·m−2, P = 0.086). Nonetheless, there were significant changes in CVP (9.3 ± 2.0 vs. 11.4 ± 3.7 mmHg, P = 0.018), CI (3.2 ± 0.7 vs. 3.9 ± 0.6 L·min−1·m−2, P < 0.001) and ScvO2 (73.4% ± 7.4% vs. 79.2% ± 5.7%, P = 0.015) after intervention to improve DO2 [Table 3].
Baseline prediction of an oxygen consumption response to improved oxygen delivery
A baseline P(v−a)CO2/C(a−v)O2 ratio ≥1.6 mmHg/ml predicted an improvement in VO2 when DO2 increased by >10%, with a sensitivity of 68.8% and a specificity of 87.5%. The AUC was 0.77 ± 0.10 [P = 0.032; Figure 2]. No other variable, including ScvO2, serum lactate or AGcorrected, significantly predicted a VO2 response [Table 3].
Figure 2.

Receiver operating characteristic (ROC) curve. ROC curve comparing the P(v−a)CO2/C(a−v)O2 ratio to an increase in oxygen consumption (VO2) brought about by increasing oxygen delivery (DO2) by >10% in cardiac surgical patients. Area under the curve: 0.77 ± 0.10, P = 0.032, The cutoff of the P(v−a)CO2/C(a−v)O2 ratio value was 1.6 for predicting cardiac surgery patients in whom VO2 would increase when DO2 increased by >10%, resulting in a sensitivity of 68.8% and a specificity of 87.5%.
DISCUSSION
Our main finding was that the P(v−a)CO2/C(a−v)O2 ratio was a reliable marker of global anaerobic metabolism in cardiac surgery patients and predicts whether improved DO2 will result in an increase in VO2. This is particularly helpful in guiding the management of patients after cardiac surgery, when hyperlactatemia might not always represent anaerobic metabolism, and a normal ScvO2 may fail to reflect persistent tissue hypoxia.[6] However, care must be exercised when seeking to elevate CO to improve DO2 in patients who have undergone cardiac surgery. The P(v−a)CO2/C(a−v)O2 ratio allows patients likely to respond to intervention to be treated appropriately without exposing those who will not to unnecessary risk. At baseline in postoperative cardiac surgery patients, a P(v−a)CO2/C(a−v)O2 ratio ≥1.6 mmHg/ml predicted a positive VO2 response when DO2 was increased by >10%, with a sensitivity of 68.8% and a specificity of 87.5%. This finding is consistent with another recent study that found that a cut-off of 1.8 mmHg/ml had a reasonable sensitivity and specificity to predict VO2 response.[7]
Physiological relevance of the P(v−a)CO2/C(a−v)O2 ratio
The P(v−a)CO2/C(a−v)O2 ratio positively correlates with the respiratory quotient (RQ). According to the Fick equation, VO2 is the product of CO and arteriovenous O2 content difference (C(a−v)O2). Carbon dioxide production (VCO2) is equal to the product of CO and veno-arterial CO2 content difference. Under most normal physiological circumstances, CO2 tension is linearly related to CO2 content, so an increase in the RQ should be reflected by an increase in the P(v−a)CO2/C(a−v)O2 ratio.[11]
During tissue hypoxia, the reduction in global O2 consumption is accompanied by diminished aerobic but increased anaerobic CO2 production, with excess protons buffered mostly by bicarbonate ions.[12] Thus, total VCO2 should be reduced less than VO2, hence, global anaerobic metabolism is reflected by increases in the RQ (VCO2/VO2) and P(v−a)CO2/C(a−v)O2 ratio.
Oxygen supply, demand and the P(v−a)CO2/C(a−v)O2 ratio
At baseline, we found that P(v−a)CO2/C(a−v)O2 ratio was higher in the VO2 increase group and predicted a response to resuscitation when ScvO2 was normal, and serum lactate concentration was raised. Under these circumstances, hyperlactatemia equates with hypoxia. Friedman et al.[8] reported that interventions to increase DO2 were justified when there was a VO2 response, and the use of the P(v−a)CO2/C(a−v)O2 ratio is underpinned by the same pathophysiological concept. Outcomes are very poor in patients with an oxygen deficit whose VO2 fails to respond to increased DO2.[13] After cardiac surgery, the postoperative course is characterized by increases in cellular oxygen demand as a consequence of rising body temperature,[14] emergence from anesthesia, and the resumption of spontaneous ventilation.[15] Shivering, pain, and anxiety may further increase oxygen demand.[16] In complex situations, plotting VO2/DO2 over time during a DO2 challenge allows the critical DO2 to be identified. This ensures that VO2 needs are met, a crucial objective even if DO2 and VO2 are estimated intuitively rather than measured directly. As DO2 increases beyond the critical point, VO2 may continue to rise slowly, rather than plateau. When oxygen requirements are excessive, DO2 becomes uncoupled from metabolic activity;[17] as CO improves during a DO2 challenge, the VO2 of the muscles and viscera increase in direct proportion to blood flow.[18,19,20] Furthermore, additional oxygen is taken up by nonmitochondrial oxidase systems as dysoxia resolves.[21] It is therefore clinically important to be able to detect a VO2 response to a DO2 challenge, especially when the extent of oxygen deficit is unclear.
P(v−a)CO2/C(a−v)O2 ratio is superior to lactate and lactate clearance rate
Hyperlactatemia on admission to ICU after cardiac surgery was found to predict mortality in some single-center studies,[22,23] but not in larger studies.[24,25] Early after CPB, hyperlactatemia may reflect intraoperative factors rather than anaerobic metabolism, a concept supported by our findings. In our study, there were no significant differences in serum lactate concentrations between the groups at baseline, or before and after the intervention.
Hyperlactatemia may not be directly caused by tissue dysoxia. There is a delay of 30–60 min between myocardial reperfusion and normalization of lactate concentration measured in the coronary sinus, suggesting that anaerobic metabolism continues within the myocardium for some time after ischemia.[26] Restoration of blood flow in animal and human models of circulatory failure results in lactate “washout” from regional tissues, especially from the coronary and renal circulations.[1] Pulmonary lactate levels rise significantly after surgical trauma and CPB, and may contribute significantly to circulating lactate levels up to 6 h postoperatively.[27] It has been hypothesized that lactate is used as a source of energy during physiological stress.[6] When lactate remains high despite evidence that a VO2 plateau has been reached, there is no evidence that increasing DO2 further is beneficial,[13] and indeed could be harmful in patients with impaired cardiac function. We observed a trend that serum lactate concentration fell after intervention, even in the group that did not mount a VO2 response, although the differences were not statistically significant. This could be explained by lactate “washout” or other factors. The kinetics of lactate clearance depends fundamentally on hepatic clearance, which appears to be preserved even during cardiogenic shock.[28]
Early recognition of shock is critical, as it responds better to intervention in the early stages,[29] and there is some evidence that rapidly achieving an adequate total body VO2 is a prerequisite of successful resuscitation. Delaying resuscitation causes macro- and microcirculatory failure and ultimately cell necrosis, which cannot be corrected by resuscitation. In shock, the oxygen deficit is only a “snapshot” calculated as the difference between baseline “normal” VO2 and the VO2 measured at a particular time; however, oxygen debt accumulates over time. The P(v−a)CO2/C(a−v)O2 ratio can be measured as a “snapshot,” whereas measuring lactate clearance rate takes time, during which patients may be exposed to prolonged periods of tissue hypoperfusion.
P(v−a)CO2/C(a−v)O2 ratio is superior to central venous oxygen saturation
An ScvO2 <60.8% is considered unsatisfactory after cardiac surgery and can be found in approximately 13% of patients. In contrast, supranormal levels >77.4% occurs in approximately one-third of patients, and appears to be a warning sign of impaired tissue oxygenation and is associated with higher mortality.[9] Patients with low ScvO2 and hyperlactatemia clearly require resuscitation, so we focused on patients with ScvO2 >61%, where the situation is less clear. We did not, however, distinguish between patients with normal and supranormal ScvO2 as the boundaries between the two are less well defined.
Assuming that “supranormal” ScvO2 indicates impaired tissue oxygenation, there are three mechanisms that are likely responsible for the co-existence of normal or supranormal ScvO2 and hyperlactatemia after cardiac surgery: CPB or off-pump surgery with concomitant mitochondrial dysfunction; therapeutic interventions to increase DO2, most notably β-mimetics;[4] and macrocirculatory failure combined with microcirculatory or mitochondrial failure. In health, VO2 is determined by the metabolic needs of the tissues and when DO2 increases VO2 remains relatively constant as the tissues adapt their ERO2 accordingly, known as oxygen supply independency. In shock, however, mitochondrial dysfunction or microvascular shunting may result in persistent anaerobic metabolism and static VO2 even as DO2 improves with resuscitation. Oxygen extraction and SvO2 (or ScvO2) are linked by a simple equation: ScvO2 = 1 − ERO2, which can be rewritten as ScvO2 = 1 − VO2/DO2 if it is assumed that SaO2 = 1. Thus, if DO2 is altered in the face of a relatively constant VO2, ScvO2 will increase, and ERO2 will fall. We found that there was a significant rise in ScvO2 in the VO2 no-increase group after intervention, but our study was unable to distinguish between patients with mitochondrial dysfunction or microcirculatory shunt and those with oxygen supply independency. Even so, further macrocirculatory resuscitation is not warranted in either case and a single baseline measurement of P(v−a)CO2/C(a−v)O2 ratio appears to be superior to ScvO2 in helping to identify patients likely to respond to intervention.
P(v−a)CO2/C(a−v)O2 ratio is superior to P(v−a)CO2
Veno-arterial PCO2 difference (P(v-a)CO2) has been proposed to be a marker of tissue hypoxia, and is also often used to guide resuscitation.[30] However, it is not clear whether it reliably identifies VO2 responders. Van der Linden et al. found a significant correlation between blood lactate levels and P(v−a)CO2 in an animal model of acute hemorrhage,[31] and progressive increases in P(v−a)CO2 have been observed during the VO2/DO2 dependent period as blood flow falls.[32]
Hypoperfusion can result in a widening of P(v−a)CO2 even if no additional CO2 production occurs, known as the CO2-stagnation phenomenon. P(v−a)CO2 could, therefore, be considered to be an indicator of adequate venous blood flow to remove CO2 produced in the peripheries.[33] In the isolated dog limb model of hypoxia, Vallet et al. found that P(v−a)CO2 was increased in ischemic hypoxia but not hypoxic hypoxia, suggesting that P(v−a)CO2 has poor sensitivity for detecting tissue hypoxia.[34] P(v-a)CO2 = k × VCO2/CO, where k is assumed to be constant. VCO2 = RQ × VO2, CO = DO2/SaO2 × 1.34 × Hb. Comprehensive the above three equations, P(v−a)CO2 = RQ × ERO2 × SaO2 × Hb × k. If arterial oxygen saturation (SaO2) and Hb remain constant, P(v-a)CO2 is influenced by RQ and ERO2. A high ERO2 (and hence low ScvO2) is associated with increased mortality in the presence of high serum lactate concentration.[6]
Although high ERO2 increases the numerical value of P(v−a)CO2, it does not reliably reflect anaerobic metabolism as there is significant individual variation in the anaerobic threshold. We found trends to suggest that P(v−a)CO2 was higher in the VO2 increase group than the VO2 no-increase group, and in the VO2 increase group before and after intervention, but the differences were not statistically significant.
P(v−a)CO2/C(a−v)O2 ratio is superior to corrected anion gap
The corrected and strong ion gaps have been advocated as surrogate markers of global anaerobic metabolism, and deficits in DO2 and cellular perfusion in cardiac critical care[35] and AG has been used as a therapeutic target in research.[36] Although the link between metabolic acidosis and tissue hypoperfusion is well-established, we found no relationship between AGcorrected and anaerobic metabolism as above.
Limitations
Our study has several limitations. First, myocardial ischemia and reperfusion injury and the effects of anesthetic drugs may limit tissue oxygen use and the CO response to DO2 challenge.[37] In addition, resuscitation was not guided by the protocol but left to the discretion of the attending physician and thus ours is an observational study, albeit an observation of routine clinical practice. Second, only a small proportion of patients met our inclusion criteria, so our findings cannot be generalized to those in whom DO2 did not respond to intervention or those with arrhythmia. A larger multi-center study will be needed to confirm our findings and determine more accurate ratio cutoff values. Third, hyperthermia, acute respiratory failure, and pain increase VO2 needs sharply. Antipyretic drugs, sedation, and mechanical ventilation[38] can reduce VO2 by up to 50%, so can have the same effect as doubling CO or ERO2. When seeking to improve DO2, it is also important to reduce VO2, but we did not examine the benefits of interventions that decrease VO2, instead we sought to identify patients able to mount a DO2 response to resuscitation. After cardiac surgery hyperlactatemia does not always reflect anaerobic metabolism, and a normal ScvO2 does not indicate that resuscitation has been adequate. We found that the P(v−a)CO2/C(a−v)O2 ratio appears to be a reliable marker of global anaerobic metabolism and predicts response to DO2 challenge, suggesting that it may be a useful resuscitation target.
In conclusion, P(v−a)CO2/C(a−v)O2 ratio appears to be a reliable marker of global anaerobic metabolism and predicts response to DO2 challenge. Thus, patients likely to benefit from resuscitation can be identified promptly, and those in whom a VO2 response is unlikely can be spared the unnecessary risks associated with fluid overload and positive inotropic drugs. The P(v−a)CO2/C(a−v)O2 ratio may, therefore, be a useful resuscitation target.
Footnotes
Edited by: Yuan-Yuan Ji
Source of Support: This study was supported by a grant from the National Health and Family Planning Commission of the People's Republic of China (Special Fund for Health Scientific Research in the Public Interest, No. 201202011).
Conflict of Interest: None declared.
REFERENCES
- 1.Leavy JA, Weil MH, Rackow EC. ‘Lactate washout’ following circulatory arrest. JAMA. 1988;260:662–4. [PubMed] [Google Scholar]
- 2.Gasparovic H, Plestina S, Sutlic Z, Husedzinovic I, Coric V, Ivancan V, et al. Pulmonary lactate release following cardiopulmonary bypass. Eur J Cardiothorac Surg. 2007;32:882–7. doi: 10.1016/j.ejcts.2007.09.001. [DOI] [PubMed] [Google Scholar]
- 3.James JH, Luchette FA, McCarter FD, Fischer JE. Lactate is an unreliable indicator of tissue hypoxia in injury or sepsis. Lancet. 1999;354:505–8. doi: 10.1016/S0140-6736(98)91132-1. [DOI] [PubMed] [Google Scholar]
- 4.Levy B, Gibot S, Franck P, Cravoisy A, Bollaert PE. Relation between muscle Na+K+ATPase activity and raised lactate concentrations in septic shock: A prospective study. Lancet. 2005;365:871–5. doi: 10.1016/S0140-6736(05)71045-X. [DOI] [PubMed] [Google Scholar]
- 5.Fink MP. Cytopathic hypoxia. Mitochondrial dysfunction as mechanism contributing to organ dysfunction in sepsis. Crit Care Clin. 2001;17:219–37. doi: 10.1016/s0749-0704(05)70161-5. [DOI] [PubMed] [Google Scholar]
- 6.Pope JV, Jones AE, Gaieski DF, Arnold RC, Trzeciak S, Shapiro NI, et al. Multicenter study of central venous oxygen saturation (ScvO (2)) as a predictor of mortality in patients with sepsis. Ann Emerg Med. 2010;55:40–6e1. doi: 10.1016/j.annemergmed.2009.08.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Monnet X, Julien F, Ait-Hamou N, Lequoy M, Gosset C, Jozwiak M, et al. Lactate and venoarterial carbon dioxide difference/arterial-venous oxygen difference ratio, but not central venous oxygen saturation, predict increase in oxygen consumption in fluid responders. Crit Care Med. 2013;41:1412–20. doi: 10.1097/CCM.0b013e318275cece. [DOI] [PubMed] [Google Scholar]
- 8.Friedman G, De Backer D, Shahla M, Vincent JL. Oxygen supply dependency can characterize septic shock. Intensive Care Med. 1998;24:118–23. doi: 10.1007/s001340050531. [DOI] [PubMed] [Google Scholar]
- 9.Perz S, Uhlig T, Kohl M, Bredle DL, Reinhart K, Bauer M, et al. Low and “supranormal” central venous oxygen saturation and markers of tissue hypoxia in cardiac surgery patients: A prospective observational study. Intensive Care Med. 2011;37:52–9. doi: 10.1007/s00134-010-1980-8. [DOI] [PubMed] [Google Scholar]
- 10.Figge J, Jabor A, Kazda A, Fencl V. Anion gap and hypoalbuminemia. Crit Care Med. 1998;26:1807–10. doi: 10.1097/00003246-199811000-00019. [DOI] [PubMed] [Google Scholar]
- 11.Mekontso-Dessap A, Castelain V, Anguel N, Bahloul M, Schauvliege F, Richard C, et al. Combination of venoarterial PCO2 difference with arteriovenous O2 content difference to detect anaerobic metabolism in patients. Intensive Care Med. 2002;28:272–7. doi: 10.1007/s00134-002-1215-8. [DOI] [PubMed] [Google Scholar]
- 12.Randall HM, Jr, Cohen JJ. Anaerobic CO2 production by dog kidney in vitro. Am J Physiol. 1966;211:493–505. doi: 10.1152/ajplegacy.1966.211.2.493. [DOI] [PubMed] [Google Scholar]
- 13.Rhodes A, Lamb FJ, Malagon I, Newman PJ, Grounds RM, Bennett ED. A prospective study of the use of a dobutamine stress test to identify outcome in patients with sepsis, severe sepsis, or septic shock. Crit Care Med. 1999;27:2361–6. doi: 10.1097/00003246-199911000-00007. [DOI] [PubMed] [Google Scholar]
- 14.Sladen RN. Temperature and ventilation after hypothermic cardiopulmonary bypass. Anesth Analg. 1985;64:816–20. [PubMed] [Google Scholar]
- 15.Tulla H, Takala J, Alhava E, Huttunen H, Kari A. Hypermetabolism after coronary artery bypass. J Thorac Cardiovasc Surg. 1991;101:598–600. [PubMed] [Google Scholar]
- 16.Zwischenberger JB, Kirsh MM, Dechert RE, Arnold DK, Bartlett RH. Suppression of shivering decreases oxygen consumption and improves hemodynamic stability during postoperative rewarming. Ann Thorac Surg. 1987;43:428–31. doi: 10.1016/s0003-4975(10)62823-8. [DOI] [PubMed] [Google Scholar]
- 17.Bihari D, Smithies M, Gimson A, Tinker J. The effects of vasodilation with prostacyclin on oxygen delivery and uptake in critically ill patients. N Engl J Med. 1987;317:397–403. doi: 10.1056/NEJM198708133170701. [DOI] [PubMed] [Google Scholar]
- 18.Jeppsson A, Ekroth R, Friberg P, Kirnö K, Milocco I, Nilsson F, et al. Renal effects of amino acid infusion in cardiac surgery. J Cardiothorac Vasc Anesth. 2000;14:51–5. doi: 10.1016/s1053-0770(00)90056-9. [DOI] [PubMed] [Google Scholar]
- 19.Jacobson ED. Effects of histamine, acetylcholine, and norepinephrine on gastric vascular resistance. Am J Physiol. 1963;204:1013–7. doi: 10.1152/ajplegacy.1963.204.6.1013. [DOI] [PubMed] [Google Scholar]
- 20.Durán WN, Renkin EM. Oxygen consumption and blood flow in resting mammalian skeletal muscle. Am J Physiol. 1974;226:173–7. doi: 10.1152/ajplegacy.1974.226.1.173. [DOI] [PubMed] [Google Scholar]
- 21.McCord JM. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med. 1985;312:159–63. doi: 10.1056/NEJM198501173120305. [DOI] [PubMed] [Google Scholar]
- 22.Duke T, Butt W, South M, Karl TR. Early markers of major adverse events in children after cardiac operations. J Thorac Cardiovasc Surg. 1997;114:1042–52. doi: 10.1016/S0022-5223(97)70018-7. [DOI] [PubMed] [Google Scholar]
- 23.Cheifetz IM, Kern FH, Schulman SR, Greeley WJ, Ungerleider RM, Meliones JN. Serum lactates correlate with mortality after operations for complex congenital heart disease. Ann Thorac Surg. 1997;64:735–8. doi: 10.1016/s0003-4975(97)00527-4. [DOI] [PubMed] [Google Scholar]
- 24.Murray D, Grant D, Murali N, Butt W. Unmeasured anions in children after cardiac surgery. J Thorac Cardiovasc Surg. 2007;133:235–40. doi: 10.1016/j.jtcvs.2006.09.017. [DOI] [PubMed] [Google Scholar]
- 25.Cheung PY, Chui N, Joffe AR, Rebeyka IM, Robertson CM. Western Canadian Complex Pediatric Therapies Project, Follow-up Group. Postoperative lactate concentrations predict the outcome of infants aged 6 weeks or less after intracardiac surgery: A cohort follow-up to 18 months. J Thorac Cardiovasc Surg. 2005;130:837–43. doi: 10.1016/j.jtcvs.2005.04.029. [DOI] [PubMed] [Google Scholar]
- 26.Amark K, Berggren H, Björk K, Ekroth A, Ekroth R, Nilsson K, et al. Blood cardioplegia provides superior protection in infant cardiac surgery. Ann Thorac Surg. 2005;80:989–94. doi: 10.1016/j.athoracsur.2005.03.095. [DOI] [PubMed] [Google Scholar]
- 27.Bendjelid K, Treggiari MM, Romand JA. Transpulmonary lactate gradient after hypothermic cardiopulmonary bypass. Intensive Care Med. 2004;30:817–21. doi: 10.1007/s00134-004-2179-7. [DOI] [PubMed] [Google Scholar]
- 28.Pearse RM, Hinds CJ. Should we use central venous saturation to guide management in high-risk surgical patients? Crit Care. 2006;10:181. doi: 10.1186/cc5122. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345:1368–77. doi: 10.1056/NEJMoa010307. [DOI] [PubMed] [Google Scholar]
- 30.Du W, Liu DW, Wang XT, Long Y, Chai WZ, Zhou X, et al. Combining central venous-to-arterial partial pressure of carbon dioxide difference and central venous oxygen saturation to guide resuscitation in septic shock. J Crit Care. 2013;28:1110e1–5. doi: 10.1016/j.jcrc.2013.07.049. [DOI] [PubMed] [Google Scholar]
- 31.Van der Linden P, Rausin I, Deltell A, Bekrar Y, Gilbart E, Bakker J, et al. Detection of tissue hypoxia by arteriovenous gradient for PCO2 and pH in anesthetized dogs during progressive hemorrhage. Anesth Analg. 1995;80:269–75. doi: 10.1097/00000539-199502000-00012. [DOI] [PubMed] [Google Scholar]
- 32.Zhang H, Vincent JL. Arteriovenous differences in PCO2 and pH are good indicators of critical hypoperfusion. Am Rev Respir Dis. 1993;148:867–71. doi: 10.1164/ajrccm/148.4_Pt_1.867. [DOI] [PubMed] [Google Scholar]
- 33.Lamia B, Monnet X, Teboul JL. Meaning of arterio-venous PCO2 difference in circulatory shock. Minerva Anestesiol. 2006;72:597–604. [PubMed] [Google Scholar]
- 34.Vallet B, Teboul JL, Cain S, Curtis S. Venoarterial CO(2) difference during regional ischemic or hypoxic hypoxia. J Appl Physiol (1985) 2000;89:1317–21. doi: 10.1152/jappl.2000.89.4.1317. [DOI] [PubMed] [Google Scholar]
- 35.Durward A, Tibby SM, Skellett S, Austin C, Anderson D, Murdoch IA. The strong ion gap predicts mortality in children following cardiopulmonary bypass surgery. Pediatr Crit Care Med. 2005;6:281–5. doi: 10.1097/01.PCC.0000163979.33774.89. [DOI] [PubMed] [Google Scholar]
- 36.Bellomo R, Lipcsey M, Calzavacca P, Haase M, Haase-Fielitz A, Licari E, et al. Early acid-base and blood pressure effects of continuous renal replacement therapy intensity in patients with metabolic acidosis. Intensive Care Med. 2013;39:429–36. doi: 10.1007/s00134-012-2800-0. [DOI] [PubMed] [Google Scholar]
- 37.Van der Linden P, Gilbart E, Engelman E, Schmartz D, Vincent JL. Effects of anesthetic agents on systemic critical O2 delivery. J Appl Physiol (1985) 1991;71:83–93. doi: 10.1152/jappl.1991.71.1.83. [DOI] [PubMed] [Google Scholar]
- 38.Miwa K, Mitsuoka M, Takamori S, Hayashi A, Shirouzu K. Continuous monitoring of oxygen consumption in patients undergoing weaning from mechanical ventilation. Respiration. 2003;70:623–30. doi: 10.1159/000075209. [DOI] [PubMed] [Google Scholar]
